Responses to polatuzumab vedotin in the salvage cohort
| Best response . | Salvage cohort (n = 54) . |
|---|---|
| OR rate* | 26 (48.1) |
| CR | 8 (14.81) |
| PR | 15 (27.78) |
| Clinical response | 3 (5.56) |
| Nonresponse rate | 28 (51.9) |
| SD | 4 (7.41) |
| MR | 3 (5.56) |
| PD | 11 (20.37) |
| Clinical progression | 10 (18.52) |
| Best response . | Salvage cohort (n = 54) . |
|---|---|
| OR rate* | 26 (48.1) |
| CR | 8 (14.81) |
| PR | 15 (27.78) |
| Clinical response | 3 (5.56) |
| Nonresponse rate | 28 (51.9) |
| SD | 4 (7.41) |
| MR | 3 (5.56) |
| PD | 11 (20.37) |
| Clinical progression | 10 (18.52) |
Objective responses specified as CR, PR, SD, MR, and PD were assessed by CT. In absence of CT scans, response assessment was based on physician’s clinical judgment including results of physical examination and laboratory assessment and documented as clinical response, clinical stable disease, or clinical progression. Response assessment with CT scans was available in 75.9% (41/54) patients. The median time of first CT response assessment was 50 d (range, 12-193 d). The median time to best CT response was 68 d (range, 12-217 d).
MR, mixed response; PD, progressive disease; SD, stable disease.
*Objective responses (including CR and PR) and clinical responses were considered as OR.